2 November 20151 MIN READ
NICE Consultation
As you may already be aware the NICE (National Institute for Health and Care Excellence) recently published interim guidance that dinutuximab (Unituxin, ch14.18/SP2/0) in combination with GM-CSF and IL-2 is not recommended for use on the NHS.
